Related Experiment Video

Updated: Jun 22, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure

Niraj Parekh1, Alan S Maisel

  • 1Department of Cardiology, Veterans Affairs Hospital, University of California at San Diego, San Diego, CA, USA.

Current Opinion in Cardiology
|June 18, 2009
PubMed

Insights

B-natriuretic peptide (BNP) effectively aids in diagnosing and predicting outcomes for diastolic heart failure. BNP levels correlate with diastolic dysfunction severity and prognosis, improving diagnostic accuracy when combined with other clinical data.

Area of Science:

  • Cardiology
  • Biochemistry
  • Medical Diagnostics

Background:

  • Diastolic heart failure, or heart failure with preserved ejection fraction, is a growing clinical concern.
  • Natriuretic peptides, particularly B-natriuretic peptide (BNP), are established biomarkers in systolic heart failure.
  • Understanding BNP's role in diastolic dysfunction is crucial for managing this prevalent condition.

Purpose of the Study:

  • To review current literature on the relationship between B-natriuretic peptide (BNP) and diastolic dysfunction.
  • To explore the diagnostic and prognostic utility of BNP in heart failure with preserved ejection fraction.

Main Methods:

  • Literature review of publications investigating BNP and diastolic dysfunction.
  • Analysis of correlations between echocardiographic parameters and serum BNP levels.
  • Examination of prognostic data related to BNP levels in decompensated diastolic heart failure.

Main Results:

  • Significant correlations exist between echocardiographic measures of diastolic dysfunction and serum BNP levels.
  • BNP levels show a linear relationship with the severity of left ventricular dysfunction.
  • Tissue Doppler imaging reveals elevated left ventricular filling pressures associated with higher BNP.
  • BNP levels at admission and discharge predict mortality and readmission in decompensated diastolic heart failure.

Conclusions:

  • BNP is a valuable tool for diagnosing and providing prognostic information in both symptomatic and asymptomatic diastolic dysfunction.
  • Combining BNP data with echocardiographic indices and cardiovascular risk factors enhances diagnostic sensitivity and specificity.
  • BNP plays a significant role in the comprehensive management of diastolic heart failure.
Abstract

More Related Videos

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice08:21

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...